Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma

• Kieron Dunleavy,
• Stefania Pittaluga,
• Margaret Shovlin,
• Mark Roschewski,
• Catherine Lai,
• Seth M. Steinberg,
• Elaine S. Jaffe,
• Wyndham H. Wilson

Affiliations

Kieron Dunleavy

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Stefania Pittaluga

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Margaret Shovlin

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Mark Roschewski

Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Catherine Lai

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Seth M. Steinberg

Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Elaine S. Jaffe

Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Wyndham H. Wilson

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA